Sandoz optimistic on biosimilars as it reprioritizes US portfolio
Sandoz US president Carol Lynch talks about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo. Sandoz International GMBHÂ is shrinking the size of its US footprint as it prioritizes complex generics ...
Potential upcoming approvals and launches of subcutaneous formulations of monoclonal antibodies could prove a boon for Halozyme, which licenses i ...
Transcenta says efforts to intensify perfusion-based mAb production platform should give it competitive edge.
It made the claim last week, als ...
Iovance will use CDMO WuXi Apptec for initial commercial supply of lifileucel, but a Philadelphia plant under-construction looks to bring its tum ...
The expansion at a cell culture facility in Research Triangle Park will feed the demand for growing biologics pipelines, says CDMO Fujifilm Diosy ...
Recent Tweets
-
RT @Dan5tanton: The expansion at a cell culture facility in Research Triangle Park will feed the demand for growing biologics pipel… https://t.co/QX8bi5MV34
1 day ago
-
RT @Dan5tanton: @AveXis has opened a gene therapy plant in Durham NC it says will be able to produce up to seven products simultane… https://t.co/pm4CdAHbFq
3 days ago
-
RT @Dan5tanton: Over a quarter of KKR's Gamma Bioscience’s $200 million funding for next-generation bioprocessing technologies will… https://t.co/S2cXORZaVT
3 days ago
-
RT @Dan5tanton: An effective quality management system is a must for biopharmaceutical firms looking to protect their data assets a… https://t.co/mdbElhX6LQ
1 week ago
Trending
Manufacturing
Challenges and Opportunities in CAR T-Cell Development and Manufacturing
Manufacturing
From Big Data to Precise Understanding: The Quest for Meaningful Information
Business
Supply and Demand Trends: Mammalian Biomanufacturing Industry Overview
Manufacturing
Do We Need Separate Regulations for Advanced Therapies?